Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.94)
# 152
Out of 12,268 analysts
256
Total ratings
67.7%
Success rate
38.7%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintained: Buy | $49 | $34.15 | +43.48% | 16 | May 25, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $28 | $13.84 | +102.31% | 5 | May 25, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $36 → $39 | $16.35 | +138.53% | 6 | May 15, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $48 → $39 | $17.24 | +126.22% | 17 | May 13, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $107 | $74.05 | +44.50% | 17 | May 12, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $332 → $328 | $247.05 | +32.77% | 16 | May 8, 2026 | |
| ACRS Aclaris Therapeutics | Maintained: Hold | $2 → $4 | $4.52 | -11.50% | 13 | May 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $83 | $36.79 | +125.60% | 11 | May 8, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,227 → $1,222 | $806.46 | +51.53% | 27 | May 7, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $40 | $22.21 | +80.10% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 | $44.43 | -3.22% | 29 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $28.36 | +51.62% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $22.87 | +136.12% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $72 → $150 | $60.61 | +147.48% | 9 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.95 | +156.41% | 3 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $22.02 | +99.82% | 4 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $81.05 | - | 13 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 → $120 | $86.48 | +38.76% | 11 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $85 | $59.71 | +42.35% | 11 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $19 | $18.19 | +4.45% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $68 | $30.73 | +121.28% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $2.26 | +121.24% | 1 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 → $114 | $78.89 | +44.51% | 9 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $1.21 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $15.20 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $35.88 | n/a | 1 | Aug 8, 2023 |
Immunovant
May 25, 2026
Maintained: Buy
Price Target: $49
Current: $34.15
Upside: +43.48%
Cullinan Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $28
Current: $13.84
Upside: +102.31%
Avalo Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $36 → $39
Current: $16.35
Upside: +138.53%
Viridian Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $48 → $39
Current: $17.24
Upside: +126.22%
Spyre Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $107
Current: $74.05
Upside: +44.50%
Ascendis Pharma
May 8, 2026
Maintained: Buy
Price Target: $332 → $328
Current: $247.05
Upside: +32.77%
Aclaris Therapeutics
May 8, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $4.52
Upside: -11.50%
Crinetics Pharmaceuticals
May 8, 2026
Maintained: Buy
Price Target: $83
Current: $36.79
Upside: +125.60%
argenx SE
May 7, 2026
Reiterated: Buy
Price Target: $1,227 → $1,222
Current: $806.46
Upside: +51.53%
Jade Biosciences
May 7, 2026
Maintained: Buy
Price Target: $40
Current: $22.21
Upside: +80.10%
May 5, 2026
Maintained: Hold
Price Target: $43
Current: $44.43
Upside: -3.22%
May 1, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $28.36
Upside: +51.62%
May 1, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $22.87
Upside: +136.12%
Apr 28, 2026
Maintained: Buy
Price Target: $72 → $150
Current: $60.61
Upside: +147.48%
Apr 4, 2026
Maintained: Buy
Price Target: $5
Current: $1.95
Upside: +156.41%
Apr 4, 2026
Maintained: Buy
Price Target: $44
Current: $22.02
Upside: +99.82%
Mar 23, 2026
Maintained: Buy
Price Target: n/a
Current: $81.05
Upside: -
Mar 10, 2026
Maintained: Buy
Price Target: $65 → $120
Current: $86.48
Upside: +38.76%
Mar 5, 2026
Maintained: Buy
Price Target: $56 → $85
Current: $59.71
Upside: +42.35%
Mar 1, 2026
Maintained: Hold
Price Target: $13 → $19
Current: $18.19
Upside: +4.45%
Feb 26, 2026
Maintained: Buy
Price Target: $58 → $68
Current: $30.73
Upside: +121.28%
Feb 25, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $2.26
Upside: +121.24%
Dec 15, 2025
Maintained: Buy
Price Target: $68 → $114
Current: $78.89
Upside: +44.51%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $1.21
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $15.20
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $35.88
Upside: n/a